Underwriters Aegis and Chardan given $614,922 greenshoe
By Angela McDaniels
Tacoma, Wash., Feb. 12 – EyeGate Pharmaceuticals, Inc. sold 683,250 shares of common stock in its initial public offering for $6.00 each for a total $4.1 million.
The underwriters have an over-allotment option for 102,487 shares, or $614,922, according to a company news release.
Aegis Capital Corp. and Chardan Capital Markets, LLC are the joint bookrunners.
The company expects the shares to begin trading on the OTCQB Venture Marketplace under the symbol "EYEGV" on Feb. 13, and the offering is expected to close on Feb. 19.
Proceeds will be used for clinical trials, safety trials, proof-of-concept trials, preclinical studies, working capital and other general corporate purposes.
EyeGate is a Waltham, Mass.-based pharmaceutical company that is focused on therapeutics and drug-delivery systems for treating eye diseases.
| Issuer: | EyeGate Pharmaceuticals, Inc.
|
| Issue: | Common stock
|
| Amount: | $4.1 million
|
| Greenshoe: | $614,922
|
| Shares: | 683,250
|
| Price: | $6.00
|
| Warrants: | No
|
| Bookrunners: | Aegis Capital Corp. and Chardan Capital Markets, LLC
|
| Pricing date: | Feb. 12
|
| Settlement date: | Feb. 19
|
| Expected listing: | OTCQB: EYEGV
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
